Ocular Therapeutix (OCUL) Competitors

ADMA Biologics (NASDAQ:ADMA) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Does the MarketBeat Community prefer ADMA or OCUL?

Ocular Therapeutix received 29 more outperform votes than ADMA Biologics when rated by MarketBeat users. However, 72.05% of users gave ADMA Biologics an outperform vote while only 70.36% of users gave Ocular Therapeutix an outperform vote.

Company	Underperform	Outperform
ADMA Biologics	Outperform Votes 415 72.05%	Underperform Votes 161 27.95%
Ocular Therapeutix	Outperform Votes 444 70.36%	Underperform Votes 187 29.64%

Do insiders and institutionals have more ownership in ADMA or OCUL?

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more risk and volatility, ADMA or OCUL?

ADMA Biologics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Is ADMA or OCUL more profitable?

ADMA Biologics has a net margin of 17.80% compared to Ocular Therapeutix's net margin of -283.74%. ADMA Biologics' return on equity of 53.20% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	17.80%	53.20%	26.07%
Ocular Therapeutix	-283.74%	-45.18%	-30.87%

Does the media refer more to ADMA or OCUL?

In the previous week, ADMA Biologics had 12 more articles in the media than Ocular Therapeutix. MarketBeat recorded 15 mentions for ADMA Biologics and 3 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.36 beat ADMA Biologics' score of 0.72 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate ADMA or OCUL?

ADMA Biologics currently has a consensus target price of $24.25, suggesting a potential upside of 10.55%. Ocular Therapeutix has a consensus target price of $16.25, suggesting a potential upside of 85.50%. Given Ocular Therapeutix's higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Ocular Therapeutix	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Which has stronger earnings & valuation, ADMA or OCUL?

ADMA Biologics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$459.38M	11.40	-$28.24M	$0.85	25.81
Ocular Therapeutix	$59.65M	23.40	-$80.74M	-$1.15	-7.62

Summary

ADMA Biologics beats Ocular Therapeutix on 13 of the 19 factors compared between the two stocks.